Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for @entity298 of XXXX : A Multicenter Study.

@entity1 @entity2723 @entity5 @entity14 @entity204 @entity1104 @entity694 @entity298
PURPOSE: The prognosis of @entity298 ( @entity298 ) from @entity14 has been improved with @entity1104 ( @entity1104 ) and hyperthermic intraperitoneal chemotherapy (HIPEC). However, benefits of postoperative chemotherapy (CT) are unclear. METHODS: This retrospective, multicenter study included 231 @entity1 treated by @entity1104 and HIPEC for isolated @entity298 of @entity694 in four expert's centers. Overall survival (OS), progression-free survival (PFS), and peritoneal recurrence-free survival (PRFS) were compared between @entity1 with adjuvant CT (started within 3  months after surgery) and @entity1 with surveillance only. RESULTS: After exclusion of 10 @entity1 for early postoperative @entity204 (4  %), 221 @entity1 were included (CT group: n  =  151; surveillance group: n  =  70). Main postoperative CT regimens (median of 6 cycles) were Folfox (28  %), Folfiri bevacizumab (24.5  %), Folfiri (16  %), and Folfiri cetuximab (12.5  %). The median OS after surgery was 43.3  months with no difference between CT and surveillance groups. In multivariate analysis, a low peritoneal @entity5 index (p  <  0.0001) and a long delay between diagnosis of @entity2723 and HIPEC (p  =  0.001) were associated with increased OS. The median PFS and PRFS were 12.4 and 17  months, respectively. At 1  year, more @entity1 were without progression (p  =  0.001) or @entity298 recurrence (0.0004) in the CT group, but with prolonged follow-up this difference was no longer significant. CONCLUSIONS: Early postoperative CT does not improve OS after @entity1104 and HIPEC for @entity694 . However, a transient effect on PFS and PRFS was observed. A subgroup of @entity1 who may benefit more from CT remain to be defined.
